"Better and personalized healthcare through AI is still a hugely challenging problem that will take an army of scientists and engineers." Photo via UH.edu

We are currently in the midst of what some have called the "wild west" of AI. Though healthcare is one of the most heavily regulated sectors, the regulation of AI in this space is still in its infancy. The rules are being written as we speak. We are playing catch-up by learning how to reap the benefits these technologies offer while minimizing any potential harms once they've already been deployed.

AI systems in healthcare exacerbate existing inequities. We've seen this play out into real-world consequences from racial bias in the American justice system and credit scoring, to gender bias in resume screening applications. Programs that are designed to bring machine "objectivity" and ease to our systems end up reproducing and upholding biases with no means of accountability.

The algorithm itself is seldom the problem. It is often the data used to program the technology that merits concern. But this is about far more than ethics and fairness. Building AI tools that take account of the whole picture of healthcare is fundamental to creating solutions that work.

The Algorithm is Only as Good as the Data

By nature of our own human systems, datasets are almost always partial and rarely ever fair. As Linda Nordling comments in a Nature article, A fairer way forward for AI in healthcare, "this revolution hinges on the data that are available for these tools to learn from, and those data mirror the unequal health system we see today."

Take, for example, the finding that Black people in US emergency rooms are 40 percent less likely to receive pain medication than are white people, and Hispanic patients are 25 percent less likely. Now, imagine the dataset these findings are based on is used to train an algorithm for an AI tool that would be used to help nurses determine if they should administer pain relief medication. These racial disparities would be reproduced and the implicit biases that uphold them would remain unquestioned, and worse, become automated.

We can attempt to improve these biases by removing the data we believe causes the bias in training, but there will still be hidden patterns that correlate with demographic data. An algorithm cannot take in the nuances of the full picture, it can only learn from patterns in the data it is presented with.

Bias Creep

Data bias creeps into healthcare in unexpected ways. Consider the fact that animal models used in laboratories across the world to discover and test new pain medications are almost entirely male. As a result, many medications, including pain medication, are not optimized for females. So, it makes sense that even common pain medications like ibuprofen and naproxen have been proven to be more effective in men than women and that women tend to experience worse side effects from pain medication than men do.

In reality, male rodents aren't perfect test subjects either. Studies have also shown that both female and male rodents' responses to pain levels differ depending on the sex of the human researcher present. The stress response elicited in rodents to the olfactory presence of a sole male researcher is enough to alter their responses to pain.

While this example may seem to be a departure from AI, it is in fact deeply connected — the current treatment choices we have access to were implicitly biased before the treatments ever made it to clinical trials. The challenge of AI equity is not a purely technical problem, but a very human one that begins with the choices that we make as scientists.

Unequal Data Leads to Unequal Benefits

In order for all of society to enjoy the many benefits that AI systems can bring to healthcare, all of society must be equally represented in the data used to train these systems. While this may sound straightforward, it's a tall order to fill.

Data from some populations don't always make it into training datasets. This can happen for a number of reasons. Some data may not be as accessible or it may not even be collected at all due to existing systemic challenges, such as a lack of access to digital technology or simply being deemed unimportant. Predictive models are created by categorizing data in a meaningful way. But because there's generally less of it, "minority" data tends to be an outlier in datasets and is often wiped out as spurious in order to create a cleaner model.

Data source matters because this detail unquestionably affects the outcome and interpretation of healthcare models. In sub-Saharan Africa, young women are diagnosed with breast cancer at a significantly higher rate. This reveals the need for AI tools and healthcare models tailored to this demographic group, as opposed to AI tools used to detect breast cancer that are only trained on mammograms from the Global North. Likewise, a growing body of work suggests that algorithms used to detect skin cancer tend to be less accurate for Black patients because they are trained mostly on images of light-skinned patients. The list goes on.

We are creating tools and systems that have the potential to revolutionize the healthcare sector, but the benefits of these developments will only reach those represented in the data.

So, what can be done?

Part of the challenge in getting bias out of data is that high volume, diverse and representative datasets are not easy to access. Training datasets that are publicly available tend to be extremely narrow, low-volume, and homogenous—they only capture a partial picture of society. At the same time, a wealth of diverse health data is captured every day in many healthcare settings, but data privacy laws make accessing these more voluminous and diverse datasets difficult.

Data protection is of course vital. Big Tech and governments do not have the best track record when it comes to the responsible use of data. However, if transparency, education, and consent for the sharing of medical data was more purposefully regulated, far more diverse and high-volume data sets could contribute to fairer representation across AI systems and result in better, more accurate results for AI-driven healthcare tools.

But data sharing and access is not a complete fix to healthcare's AI problem. Better and personalized healthcare through AI is still a hugely challenging problem that will take an army of scientists and engineers. At the end of the day, we want to teach our algorithms to make good choices but we are still figuring out what good choices should look like for ourselves.

AI presents the opportunity to bring greater personalization to healthcare, but it equally presents the risk of entrenching existing inequalities. We have the opportunity in front of us to take a considered approach to data collection, regulation, and use that will provide a fuller and fairer picture and enable the next steps for AI in healthcare.

------

Angela Wilkins is the executive director of the Ken Kennedy Institute at Rice University.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Health tech startup launches Houston study improve stroke patients recovery

now enrolling

A Houston-born company is enrolling patients in a study to test the efficacy of nerve stimulation to improve outcomes for stroke survivors.

Dr. Kirt Gill and Joe Upchurch founded NeuraStasis in 2021 as part of the TMC Biodesign fellowship program.

“The idea for the company manifested during that year because both Joe and I had experiences with stroke survivors in our own lives,” Gill tells InnovationMap. It began for Gill when his former college roommate had a stroke in his twenties.

“It’s a very unpredictable, sudden disease with ramifications not just for my best friend but for everyone in his life. I saw what it did to his family and caregivers and it's one of those things that doesn't have as many solutions for people to continue recovery and to prevent damage and that's an area that I wanted to focus myself on in my career,” Gill explains.

Gill and Upchurch arrived at the trigeminal and vagus nerves as a potential key to helping stroke patients. Gill says that there is a growing amount of academic literature that talks about the efficacy of stimulating those nerves. The co-founders met Dr. Sean Savitz, the director of the UTHealth Institute for Stroke and Cerebrovascular Diseases, during their fellowship. He is now their principal investigator for their clinical feasibility study, located at his facility.

The treatment is targeted for patients who have suffered an ischemic stroke, meaning that it’s caused by a blockage of blood flow to the brain.

“Rehabilitation after a stroke is intended to help the brain develop new networks to compensate for permanently damaged areas,” Gill says. “But the recovery process typically slows to essentially a standstill or plateau by three to six months after that stroke. The result is that the majority of stroke survivors, around 7.6 million in the US alone, live with a form of disability that prevents complete independence afterwards.”

NeuraStasis’ technology is intended to help patients who are past that window. They accomplish that with a non-invasive brain-stimulation device that targets the trigeminal and vagus nerves.

“Think of it kind of like a wearable headset that enables stimulation to be delivered, paired to survivors going through rehabilitation action. So the goal here is to help reinforce and rewire networks as they're performing specific tasks that they're looking to improve upon,” Gill explains.

The study, which hopes to enroll around 25 subjects, is intended to help people with residual arm and hand deficits six months or more after their ischemic stroke. The patients enrolled will receive nerve stimulation three times a week for six weeks. It’s in this window that Gill says he hopes to see meaningful improvement in patients’ upper extremity deficits.

Though NeuraStasis currently boasts just its two co-founders as full-time employees, the company is seeing healthy growth. It was selected for a $1.1 million award from the National Institutes of Health through its Blueprint MedTech program. The award was funded by the National Institute of Neurological Disorders and Stroke. The funding furthers NeuraStasis’ work for two years, and supports product development for work on acute stroke and for another product that will aid in emergency situations.

Gill says that he believes “Houston has been tailor-made for medical healthcare-focused innovation.”

NeuraStasis, he continues, has benefited greatly from its advisors and mentors from throughout the TMC, as well as the engineering talent from Rice, University of Houston and Texas A&M. And the entrepreneur says that he hopes that Houston will benefit as much from NeuraStasis’ technology as the company has from its hometown.

“I know that there are people within the community that could benefit from our device,” he says.

Texas Space Commission launches, Houston execs named to leadership

future of space

Governor Greg Abbott announced the Texas Space Commission, naming its inaugural board of directors and Texas Aerospace Research and Space Economy Consortium Executive Committee.

The announcement came at NASA's Johnson Space Center, and the governor was joined by Speaker Dade Phelan, Representative Greg Bonnen, Representative Dennis Paul, NASA's Johnson Space Center Director Vanessa Wyche, and various aerospace industry leaders.

According to a news release, the Texas Space Commission will aim to strengthen commercial, civil, and military aerospace activity by promoting innovation in space exploration and commercial aerospace opportunities, which will include the integration of space, aeronautics, and aviation industries as part of the Texas economy.

The Commission will be governed by a nine-member board of directors. The board will also administer the legislatively created Space Exploration and Aeronautics Research Fund to provide grants to eligible entities.

“Texas is home to trailblazers and innovators, and we have a rich history of traversing the final frontier: space,” Lieutenant Governor Dan Patrick says in a news release. “Texas is and will continue to be the epicenter for the space industry across the globe, and I have total confidence that my appointees to the Texas Space Commission Board of Directors and the Texas Aerospace Research and Space Economy Consortium Executive Committee will ensure the Texas space industry remains an international powerhouse for cutting-edge space innovation.”

TARSEC will independently identify research opportunities that will assist the state’s position in aeronautics research and development, astronautics, space commercialization, and space flight infrastructure. It also plans to fuel the integration of space, aeronautics, astronautics, and aviation industries into the Texas economy. TARSEC will be governed by an executive committee and will be composed of representatives of each higher education institution in the state.

“Since its very inception, NASA’s Johnson Space Center has been home to manned spaceflight, propelling Texas as the national leader in the U.S. space program,” Abbott says during the announcement. “It was at Rice University where President John F. Kennedy announced that the U.S. would put a man on the moon—not because it was easy, but because it was hard.

"Now, with the Texas Space Commission, our great state will have a group that is responsible for dreaming and achieving the next generation of human exploration in space," he continues. "Texas is the launchpad for Mars, innovating the technology that will colonize humanity’s first new planet. As we look into the future of space, one thing is clear: those who reach for the stars do so from the great state of Texas. I look forward to working with the Texas Space Commission, and I thank the Texas Legislature for partnering with industry and higher education institutions to secure the future of Texas' robust space industry."

The Houston-area board of directors appointees included:

  • Gwen Griffin, chief executive officer of the Griffin Communications Group
  • John Shannon, vice president of Exploration Systems at the Boeing Company
  • Sarah "Sassie" Duggleby, co-founder and CEO of Venus Aerospace
  • Kirk Shireman, vice president of Lunar Exploration Campaigns at Lockheed Martin
  • Dr. Nancy Currie-Gregg, director of the Texas A&M Space Institute

Additionally, a few Houstonians were named to the TARSEC committee, including:

  • Stephanie Murphy, CEO and executive chairman of Aegis Aerospace
  • Matt Ondler, president and former chief technology officer at Axiom Space
  • Jack “2fish” Fischer, vice president of production and operations at Intuitive Machines
  • Brian Freedman, president of the Bay Area Houston Economic Partnership and vice chairman of Wellby Financial
  • David Alexander, professor of physics and astronomy and director of the Rice Space Institute at Rice University

To see the full list of appointed board and committee members, along with their extended bios, click here.